Trial Profile

Phase 3 trial for ORIC-114 in 1L NSCLC in EGFR exon 20, HER2 exon 20, and/or atypical EGFR mutations

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enozertinib (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors ORIC Pharmaceuticals

Most Recent Events

04 Mar 2025 New trial record
25 Feb 2025 According to ORIC Pharmaceuticals media release, ORIC-114 registrational development plans to focus on 1L NSCLC with anticipated initiation in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com